background
acut
respiratori
tract
infect
ari
present
signific
morbid
pose
global
health
burden
patient
frequent
treat
antibiot
although
ari
commonli
caus
viru
strengthen
need
improv
diagnost
method
object
detect
viral
bacteri
rna
nasopharyng
aspir
npa
children
age
month
ari
use
ncounter
studi
design
customdesign
ncounter
probeset
contain
viral
bacteri
target
test
npa
ari
patient
result
initi
spike
control
viral
rna
detect
ng
input
rna
indic
absenc
inhibitor
npa
ncounter
appli
larger
npa
sampl
n
enabl
multiplex
detect
differ
pathogen
rna
virus
parainfluenza
viru
piv
rsv
ab
human
metapneumoviru
hmpv
bocaviru
bov
cov
influenza
viru
iv
rhinoviru
rv
sampl
respect
rsv
ab
confirm
real
time
pcr
agreement
dna
viru
av
detect
rna
level
reflect
viral
replic
sampl
bacteri
transcript
staphylococcu
aureu
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
mycoplasma
pneumonia
chlamydophila
pneumonia
detect
sampl
respect
conclus
ncounter
robust
sensit
simultan
detect
viral
rna
dna
bacteri
transcript
npa
low
rna
input
ng
mediumthroughput
techniqu
increas
understand
ari
pathogenesi
may
provid
evidencebas
approach
target
ration
use
antibiot
pediatr
ari
acut
respiratori
tract
infect
ari
account
high
mortal
morbid
children
year
old
develop
countri
acut
morbid
assign
ari
identif
etiolog
agent
case
common
upper
respiratori
tract
infect
commonli
caus
viru
case
attribut
bacteria
nonetheless
patient
treat
antibiot
respiratori
virus
diagnos
cultur
antibodybas
nucleic
acidbas
detect
method
polymeras
chain
reaction
pcr
widespread
techniqu
pathogen
identif
howev
simultan
detect
differ
pathogen
multiplex
pcr
demand
reaction
standard
end
ncounter
nanostr
technolog
digit
mrna
express
profil
method
overcom
drawback
identifi
genet
materi
use
two
probe
one
anchor
genet
materi
anchor
singular
bar
code
identifi
target
specif
hybrid
upon
bar
code
http
elsevi
bv
right
reserv
hybrid
presenc
frequenc
target
reveal
multipl
barcod
reaction
allow
multiplex
analysi
design
codeset
quantif
viral
rv
rsv
b
iv
b
piv
type
av
type
hmpv
bov
cov
bacteri
streptococcu
pneumonia
haemophilu
influenza
moraxella
catarrhali
staphylococcu
aureu
mycoplasma
pneumonia
chlamydia
pneumonia
transcript
one
multiplex
reaction
employ
nasopharing
aspir
npa
children
present
ari
studi
compli
guidelin
declar
helsinki
approv
institut
review
board
universidad
feder
da
bahia
ufba
written
inform
consent
obtain
legal
guardian
prospect
cohort
studi
involv
sampl
children
age
month
seen
ufba
emerg
unit
communitydwel
patient
fulfil
inclus
criteria
fever
cough
sneez
nasal
obstruct
period
seven
day
without
previou
episod
wheez
enrol
npa
collect
control
sampl
nasopharyng
wash
obtain
individu
n
undergo
routin
outpati
visit
collect
sampl
place
nuclisen
lysi
buffer
biomerieux
frozen
c
viral
bacteri
detect
npa
perform
use
ncounter
transcriptom
analysi
nanostr
technolog
allow
us
simultan
assay
viral
bacteri
target
total
rna
ng
obtain
subset
randomli
select
npa
extract
use
rneasi
follow
instruct
subsequ
hybrid
probe
target
rv
rsvab
iv
ab
piv
type
av
type
hmpv
bov
cov
pneumonia
h
influenza
catarrhali
aureu
c
pneumonia
tabl
synthes
nanostr
technolog
hybrid
also
perform
control
viral
bacteri
rna
pool
kindli
donat
k
bruyninckx
uz
leuven
three
differ
concentr
ng
viral
rna
ng
bacteri
rna
rsv
b
independ
quantifi
realtim
pcr
describ
raw
data
preprocess
use
nsolver
softwar
nanostr
technolog
nanostringnorm
r
packag
preprocess
sequenti
correct
three
factor
technic
variat
background
sampl
content
first
use
set
exogen
posit
control
rna
present
sampl
see
also
fig
technic
variat
account
adjust
count
sampl
geometr
mean
count
posit
control
count
sampl
subsequ
background
correct
perform
subtract
maximum
count
valu
neg
control
probe
sampl
probe
output
within
sampl
transcript
count
neg
background
correct
set
sampl
normal
rna
content
adjust
count
geometr
mean
housekeep
gene
supplementari
tabl
final
data
log
transform
full
detail
step
found
supplementari
inform
waggott
et
al
network
data
design
associ
matrix
graph
file
creat
use
gephi
node
align
forc
atla
algorithm
central
calcul
between
statist
analys
perform
use
graphpad
prism
version
digit
ncounter
profil
technolog
captur
count
specif
nucleic
acid
molecul
complex
mixtur
briefli
uniqu
pair
captur
detect
probe
design
gene
interest
captur
probe
consist
sequenc
complimentari
target
pathogen
mrna
short
common
sequenc
coupl
affin
tag
biotin
report
probe
also
contain
complementari
sequenc
coupl
colorcod
tag
provid
detect
signal
color
code
tag
uniqu
allow
accur
discrimin
differ
target
complex
mixtur
captur
report
probe
mix
total
rna
singl
hybrid
reaction
result
format
tripartit
structur
target
bound
specif
report
captur
probe
unhybrid
probe
wash
away
remain
complex
expos
streptavidin
target
bound
specif
probe
immobil
solid
surfac
scan
uniqu
report
probe
identifi
target
level
express
measur
digit
readout
transcript
count
reaction
occur
absenc
nucleic
acid
amplif
andor
enzymat
reaction
estim
target
concentr
ncounter
use
seri
posit
control
cover
rang
known
concentr
fm
compar
copi
per
cell
base
count
obtain
known
concentr
concentr
mrna
transcript
estim
estim
done
plot
count
obtain
posit
control
versu
concentr
test
fit
regress
line
averag
fig
regress
line
allow
quantif
mrna
transcript
concentr
correl
count
posit
control
concentr
lower
concentr
rang
next
assess
potenti
ncounter
diagnost
techniqu
ari
pilot
experi
use
rna
obtain
npa
four
patient
set
probe
customdesign
tabl
detect
presenc
av
cov
rsvb
fig
wherea
bov
piv
rsva
iv
ab
hmpv
rv
detect
none
four
sampl
initi
test
detect
also
posit
npa
spike
known
viral
rna
ng
indic
absenc
inhibitor
rna
isol
npa
fig
addit
use
trna
rna
carrier
ari
sampl
improv
viral
detect
supplementari
fig
confirm
even
npa
contain
low
input
rna
ng
suitabl
bacteri
rna
h
influenza
catarrhali
pneumonia
aureu
pneumonia
also
detect
control
npa
fig
comparison
purpos
perform
rsv
b
detect
realtim
pcr
agreement
ncounter
realtim
pcr
rsva
kappa
rsvb
kappa
tabl
rna
count
detect
ncounter
significantli
correl
number
copi
detect
realtim
pcr
rsva
r
spearman
p
rsvb
r
spearman
p
expand
ncounter
analysi
set
randomli
select
npa
includ
seven
healthi
control
sampl
fig
use
extend
group
detect
rv
sampl
bov
cov
iv
hmpv
piv
genotyp
rsv
b
addit
detect
dna
viru
av
type
confirm
rna
level
sampl
indic
ongo
intracellular
viral
replic
transcript
c
pneumonia
catarrhali
pneumonia
pneumonia
detect
sampl
respect
h
influenza
aureu
transcript
ubiquit
sampl
respect
also
detect
healthi
control
sampl
respect
use
data
set
observ
bacteri
presenc
major
children
wherea
children
virus
bacteria
present
fig
low
percentag
children
present
virus
upon
observ
number
transcript
per
type
pathogen
fig
av
rsb
b
show
network
analysi
also
reveal
complex
interact
occur
individu
virus
bacteria
detect
npa
fig
exampl
strongest
link
observ
bacteria
h
influenza
aureu
secondli
h
influenza
aureu
h
influenza
pneumonia
compar
viru
bacteria
influenza
show
strong
interact
rsv
b
aureu
note
interact
cov
differ
observ
cov
result
demonstr
ncounter
robust
mediumthroughput
techniqu
detect
viral
bacteri
rna
transcript
ari
patient
sensit
reproduc
ncounter
alreadi
compar
openarray
affymetrix
microarray
taqman
pcr
latter
ncounter
equal
reproduc
sensit
regard
detect
differenti
modul
gene
howev
ncounter
detect
low
abund
transcript
detect
microarray
ncounter
also
success
use
detect
pathogen
rna
transcript
clinic
sampl
import
advantag
transcript
detect
without
need
purif
amplif
yield
rapid
indic
pathogen
replic
transcriptom
profil
ncounter
allow
simultan
detect
viral
bacteri
transcript
ari
patient
detect
presenc
av
bov
cov
iv
hmpv
piv
rv
rsvab
associ
respiratori
tract
infect
knowledg
first
descript
detect
pathogen
dna
viru
adenoviru
type
rna
level
clinic
sampl
contrast
standard
dna
pcr
quantifi
dna
mostli
extracellular
viral
particl
ncounter
enabl
demonstr
ongo
intracellular
viral
replic
hypothes
relev
ari
pathogenesi
also
simultan
detect
transcript
c
pneumonia
catarrhali
pneumonia
commonli
isol
respiratori
tract
h
influenza
observ
good
agreement
realtim
pcr
ncounter
rsv
b
detect
reinforc
possibl
use
latter
altern
method
pathogen
detect
note
rsva
strain
present
high
variabl
target
use
detect
g
protein
domain
also
brazil
could
explain
weaker
correl
observ
ncounter
realtim
pcr
compar
rsvb
healthi
upper
respiratori
tract
colon
commens
potenti
pathogen
kept
check
immun
system
evid
viral
respiratori
infect
stimul
increas
bacteri
load
associ
lead
secondari
complic
preterm
infant
rsv
bacteri
coinfect
hospit
longer
period
frequent
admit
intens
care
unit
compar
children
infect
rsv
alon
sampl
major
ari
patient
present
h
influenza
aureu
togeth
pneumonia
catarrhali
usual
opportunist
pathogen
codetect
rsv
inde
transcript
agent
detect
npa
sampl
children
ari
network
analysi
show
strong
link
piv
h
influenza
rsv
b
pneumonia
exampl
pneumonia
rsv
activ
inflammasom
pneumonia
trigger
nfkb
activ
lead
inflammatori
respons
wherea
rsv
infect
result
strong
interferon
respons
possibl
overlap
signal
pathway
trigger
pathogen
may
synerg
amplifi
inflammatori
signal
coinfect
exacerb
immun
respons
could
accentu
damag
situ
increas
morbid
given
scenario
know
effect
pathogen
load
shown
ncounter
contribut
toward
understand
contribut
pathogen
diseas
sever
proofofprincipl
group
alreadi
use
ncounter
simultan
quantifi
human
retrovir
transcriptom
thu
reveal
intact
ifn
signal
infect
conclud
ncounter
use
altern
mediumthroughput
method
identifi
singl
reaction
presenc
multipl
pathogen
npa
ari
patient
given
respiratori
infect
one
common
reason
visit
physician
improv
diagnost
method
ncounter
contribut
better
patient
manag
moreov
transcriptom
approach
involv
pathogen
detect
discuss
immun
respons
transcript
enabl
identif
biomark
ari
clinic
sampl
even
present
low
rna
yield
ng
npa
approach
combin
longterm
clinic
followup
increas
understand
ari
pathogenesi
diseas
progress
wheez
ing
asthma
importantli
provid
evidencebas
approach
target
ration
use
antibiot
pediatr
ari
work
support
de
amparo
pesquisa
estado
da
bahia
fapesb
grant
kff
support
fellowship
scienc
without
border
conselho
nacion
de
desenvolvimento
e
cnpq
fapesb
rk
support
fellowship
cnpq
ab
cnc
cio
senior
investig
cnpq
studi
compli
guidelin
declar
helsinki
approv
institut
review
board
universidad
feder
da
bahia
ufba
written
inform
consent
obtain
legal
guardian
